Cargando…

IL-36 s in the colorectal cancer: is interleukin 36 good or bad for the development of colorectal cancer?

BACKGROUND AND AIMS: Colorectal cancer (CRC) is a major killer. Host immunity is important in tumorigenesis. Direct comparison among IL-36α, IL-36β and IL-36γ in the prognosis of CRC is unclear. METHODS: CRC tissue arrays were generated from colorectostomy samples with TNM stage, invasion depth and...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Feier, Qu, Meng, Zhang, Feng, Tan, Zhenyu, Xia, Qinghua, Hambly, Brett D., Bao, Shisan, Tao, Kun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6998229/
https://www.ncbi.nlm.nih.gov/pubmed/32013927
http://dx.doi.org/10.1186/s12885-020-6587-z
_version_ 1783493818827407360
author Chen, Feier
Qu, Meng
Zhang, Feng
Tan, Zhenyu
Xia, Qinghua
Hambly, Brett D.
Bao, Shisan
Tao, Kun
author_facet Chen, Feier
Qu, Meng
Zhang, Feng
Tan, Zhenyu
Xia, Qinghua
Hambly, Brett D.
Bao, Shisan
Tao, Kun
author_sort Chen, Feier
collection PubMed
description BACKGROUND AND AIMS: Colorectal cancer (CRC) is a major killer. Host immunity is important in tumorigenesis. Direct comparison among IL-36α, IL-36β and IL-36γ in the prognosis of CRC is unclear. METHODS: CRC tissue arrays were generated from colorectostomy samples with TNM stage, invasion depth and the demography of these patients (n = 185). Using immunohistochemistry/histopathology, IL-36α, IL-36β and IL-36γ were determined, in comparison to non-cancer tissues. RESULTS: A significant association was observed between colonic IL-36α, IL-36β or IL-36γ and the presence of cancer (with all P < 0.0001). Using ROC curve analysis, specificity and sensitivity of IL-36α, IL-36β or IL-36γ were confirmed, with area under the curve (AUC) values of 0.68, 0.73 and 0.65, respectively. Significant differences in survival were observed between IL-36α(high) and IL-36α(low) (P = 0.003) or IL-36γ(high) and IL-36γ(low) (P = 0.03). Survival curves varied significantly when further stratification into sub-groups, on the basis of combined levels of expression of two isotypes of IL-36 was undertaken. A significant difference was observed when levels of IL-36α and IL-36β were combined (P = 0.01), or a combination of IL-36α plus IL-36γ (P = 0.002). The sub-groups with a combination of IL-36α(high) plus IL-36β(high), or IL-36α(high) plus IL-36γ(low) exhibited the longest survival time among CRC patients. In contrast, the sub-groups of IL-36α(low) plus IL-36β(high) or IL-36α(low) plus IL-36γ(high) had the shortest overall survival. Using the log-rank test, IL-36α(high) expression significantly improved survival in patients with an invasion depth of T4 (P < 0.0001), lymph node metastasis (P = 0.04), TNM III-IV (P = 0.03) or with a right-sided colon tumour (P = 0.02). Similarly, IL-36γ(low) expression was significantly associated with improved survival in patients with no lymph node metastasis (P = 0.008), TNM I-II (P = 0.03) or with a left-sided colon tumour (P = 0.05). Multivariate analysis demonstrated that among IL-36α, IL-36β and IL-36γ, only IL-36α (HR, 0.37; 95% CI, 0.16–0.87; P = 0.02) was an independent factor in survival, using Cox proportional hazards regression analysis. CONCLUSION: IL-36α or IL-36γ are reliable biomarkers in predicting the prognosis of CRC during the later or early stages of the disease, respectively. Combining IL-36α plus IL-36γ appears to more accurately predict the postoperative prognosis of CRC patients. Our data may be useful in the management of CRC.
format Online
Article
Text
id pubmed-6998229
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69982292020-02-05 IL-36 s in the colorectal cancer: is interleukin 36 good or bad for the development of colorectal cancer? Chen, Feier Qu, Meng Zhang, Feng Tan, Zhenyu Xia, Qinghua Hambly, Brett D. Bao, Shisan Tao, Kun BMC Cancer Research Article BACKGROUND AND AIMS: Colorectal cancer (CRC) is a major killer. Host immunity is important in tumorigenesis. Direct comparison among IL-36α, IL-36β and IL-36γ in the prognosis of CRC is unclear. METHODS: CRC tissue arrays were generated from colorectostomy samples with TNM stage, invasion depth and the demography of these patients (n = 185). Using immunohistochemistry/histopathology, IL-36α, IL-36β and IL-36γ were determined, in comparison to non-cancer tissues. RESULTS: A significant association was observed between colonic IL-36α, IL-36β or IL-36γ and the presence of cancer (with all P < 0.0001). Using ROC curve analysis, specificity and sensitivity of IL-36α, IL-36β or IL-36γ were confirmed, with area under the curve (AUC) values of 0.68, 0.73 and 0.65, respectively. Significant differences in survival were observed between IL-36α(high) and IL-36α(low) (P = 0.003) or IL-36γ(high) and IL-36γ(low) (P = 0.03). Survival curves varied significantly when further stratification into sub-groups, on the basis of combined levels of expression of two isotypes of IL-36 was undertaken. A significant difference was observed when levels of IL-36α and IL-36β were combined (P = 0.01), or a combination of IL-36α plus IL-36γ (P = 0.002). The sub-groups with a combination of IL-36α(high) plus IL-36β(high), or IL-36α(high) plus IL-36γ(low) exhibited the longest survival time among CRC patients. In contrast, the sub-groups of IL-36α(low) plus IL-36β(high) or IL-36α(low) plus IL-36γ(high) had the shortest overall survival. Using the log-rank test, IL-36α(high) expression significantly improved survival in patients with an invasion depth of T4 (P < 0.0001), lymph node metastasis (P = 0.04), TNM III-IV (P = 0.03) or with a right-sided colon tumour (P = 0.02). Similarly, IL-36γ(low) expression was significantly associated with improved survival in patients with no lymph node metastasis (P = 0.008), TNM I-II (P = 0.03) or with a left-sided colon tumour (P = 0.05). Multivariate analysis demonstrated that among IL-36α, IL-36β and IL-36γ, only IL-36α (HR, 0.37; 95% CI, 0.16–0.87; P = 0.02) was an independent factor in survival, using Cox proportional hazards regression analysis. CONCLUSION: IL-36α or IL-36γ are reliable biomarkers in predicting the prognosis of CRC during the later or early stages of the disease, respectively. Combining IL-36α plus IL-36γ appears to more accurately predict the postoperative prognosis of CRC patients. Our data may be useful in the management of CRC. BioMed Central 2020-02-03 /pmc/articles/PMC6998229/ /pubmed/32013927 http://dx.doi.org/10.1186/s12885-020-6587-z Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Chen, Feier
Qu, Meng
Zhang, Feng
Tan, Zhenyu
Xia, Qinghua
Hambly, Brett D.
Bao, Shisan
Tao, Kun
IL-36 s in the colorectal cancer: is interleukin 36 good or bad for the development of colorectal cancer?
title IL-36 s in the colorectal cancer: is interleukin 36 good or bad for the development of colorectal cancer?
title_full IL-36 s in the colorectal cancer: is interleukin 36 good or bad for the development of colorectal cancer?
title_fullStr IL-36 s in the colorectal cancer: is interleukin 36 good or bad for the development of colorectal cancer?
title_full_unstemmed IL-36 s in the colorectal cancer: is interleukin 36 good or bad for the development of colorectal cancer?
title_short IL-36 s in the colorectal cancer: is interleukin 36 good or bad for the development of colorectal cancer?
title_sort il-36 s in the colorectal cancer: is interleukin 36 good or bad for the development of colorectal cancer?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6998229/
https://www.ncbi.nlm.nih.gov/pubmed/32013927
http://dx.doi.org/10.1186/s12885-020-6587-z
work_keys_str_mv AT chenfeier il36sinthecolorectalcancerisinterleukin36goodorbadforthedevelopmentofcolorectalcancer
AT qumeng il36sinthecolorectalcancerisinterleukin36goodorbadforthedevelopmentofcolorectalcancer
AT zhangfeng il36sinthecolorectalcancerisinterleukin36goodorbadforthedevelopmentofcolorectalcancer
AT tanzhenyu il36sinthecolorectalcancerisinterleukin36goodorbadforthedevelopmentofcolorectalcancer
AT xiaqinghua il36sinthecolorectalcancerisinterleukin36goodorbadforthedevelopmentofcolorectalcancer
AT hamblybrettd il36sinthecolorectalcancerisinterleukin36goodorbadforthedevelopmentofcolorectalcancer
AT baoshisan il36sinthecolorectalcancerisinterleukin36goodorbadforthedevelopmentofcolorectalcancer
AT taokun il36sinthecolorectalcancerisinterleukin36goodorbadforthedevelopmentofcolorectalcancer